medigraphic.com
Instituto Nacional de Salud Pública

2018, Número 6

<< Anterior Siguiente >>

salud publica mex 2018; 60 (6)


Incidencia de lesiones genitales externas relacionadas con el virus del papiloma humano entre hombres mexicanos. Un estudio de cohorte

Lazcano-Ponce E, Sudenga SL, Torres BN, Stoler M, León-Maldonado L, Allen-Leigh B, Posso H, Quiterio M, Hernández-Nevarez MP, Salmerón J, Giuliano AR

Idioma: Ingles.
Referencias bibliográficas: 39
Paginas: 633-644
Archivo PDF: 534.76 Kb.


RESUMEN

Objetivo. Determinar incidencia de lesiones genitales externas (LGE) –condiloma y neoplasia intraepitelial del pene (NIP)– y progresión de genotipos de VPH a LGE. Material y métodos. Se aplicaron cuestionarios, examen anogenital y recolección de muestras cada seis meses a hombres sanos (18-74 años, de Cuernavaca, México, reclutados 2005-2009, n=954) con biopsia y confirmación histológica. Se caracterizaron 37 tipos de ADN-VPH; se calculó incidencia de LGE (cumulativa con Kaplan-Meier). Resultados. Incidencia de LGE=1.84 (IC95%=1.42-2.39) por 100-persona-años (pa); 2.9% (IC95%=1.9-4.2) LGE acumulativa a 12 meses. Mayor incidencia de LGE entre hombres 18-30 años; 1.99 (IC95%=1.22-3.25) por 100pa. Siete sujetos tuvieron NIP I-III. VPH-11 más comúnmente progresa a condiloma (incidencia acumulativa a seis meses=44.4%, IC95%=14.3-137.8). Los sujetos con comportamiento sexual de alto riesgo tuvieron mayor incidencia de LGE. Conclusiones. En México la in fección anogenital con VPH es alta y puede causar condiloma. La estimación de magnitud de LGE y los costos sanitarios asociados se necesita para evaluar la necesidad de vacunación contra VPH en hombres.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis. 2007;196(10):1447-54. https://doi.org/10.1086/522863

  2. Dinh TH, Sternberg M, Dunne EF, Markowitz LE. Genital warts among 18- to 59-year-olds in the United States, national health and nutrition examination survey, 1999-2004. Sex Transm Dis. 2008;35(4):357-60. https:// doi.org/10.1097/OLQ.0b013e3181632d61

  3. Kraut AA, Schink T, Schulze-Rath R, Mikolajczyk RT, Garbe E. Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect Dis. 2010;10:360. https://doi.org/10.1186/1471-2334-10-360

  4. Dominiak-Felden G, Gobbo C, Simondon F. Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: A cohort study. PLoS One. 2015;10(7):e0132404. https://doi.org/10.1371/journal. pone.0132404

  5. Mikolajczyk RT, Kraut AA, Horn J, Schulze-Rath R, Garbe E. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study. Sex Transm Dis. 2013;40(1):28-31. https://doi.org/10.1097/OLQ.0b013e3182756efd

  6. Park IU, Introcaso C, Dunne EF. Human Papillomavirus and genital warts: A review of the evidence for the 2015 centers for disease control and prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. 2015;61(suppl 8):S849-55. https://doi.org/10.1093/cid/civ813

  7. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805-14. https://doi.org/10.1086/597071

  8. Stensen S, Kjaer SK, Jensen SM, Frederiksen K, Junge J, Iftner T, et al. Factors associated with type-specific persistence of high-risk human papillomavirus infection: A population-based study. Int J Cancer. 2016;138(2):361-8. https://doi.org/10.1002/ijc.29719

  9. Bollerup S, Baldur-Felskov B, Blomberg M, Baandrup L, Dehlendorff C, Kjaer SK. Significant reduction in the incidence of genital warts in young men 5 years into the Danish Human Papillomavirus Vaccination Program for girls and women. Sex Transm Dis. 2016;43(4):238-42. https://doi. org/10.1097/OLQ.0000000000000418

  10. Chow EP, Read TR, Wigan R, Donovan B, Chen MY, Bradshaw CS, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015;91(3):214-9. https://doi.org/10.1136/sextrans- 2014-051813

  11. Sudenga SL, Ingles DJ, Pierce-Campbell CM, Lin HY, Fulp WJ, Messina JL, et al. Genital Human Papillomavirus infection progression to external genital lesions: The HIM Study. Eur Urol. 2016;69(1):166-73. https://doi. org/10.1016/j.eururo.2015.05.032

  12. Giuliano AR, Lazcano E, Villa LL, Flores R, Salmeron J, Lee JH, et al. Circumcision and sexual behavior: factors independently associated with human papillomavirus detection among men in the HIM study. Int J Cancer. 2009;124(6):1251-7. https://doi.org/10.1002/ijc.24097

  13. Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet. 2011;377(9769):932-40. https://doi. org/10.1016/S0140-6736(10)62342-2

  14. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol. 1998;36(10):3020-7.

  15. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6(4):204. https://doi.org/10.1016/ S1470-2045(05)70086-3

  16. Anic GM, Messina JL, Stoler MH, Rollison DE, Stockwell H, Villa LL, et al. Concordance of human papillomavirus types detected on the surface and in the tissue of genital lesions in men. J Med Virol. 2013;85(9):1561-6. https://doi.org/10.1002/jmv.23635

  17. Coutlée F, Rouleau D, Petignat P, Ghattas G, Kornegay JR, Schlag P, et al. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. J Clin Microbiol. 2006;44(6):1998-2006. https://doi.org/10.1128/ JCM.00104-06

  18. Ying Z, Wei L. The Kaplan-Meier estimate for dependent failure time observations. J Multivar Anal. 1994;50(1):17-29. https://doi.org/10.1006/ jmva.1994.1031

  19. Woodhall SC, Jit M, Soldan K, Kinghorn G, Gilson R, Nathan M, et al. The impact of genital warts: loss of quality of life and cost of treatment in eight sexual health clinics in the UK. Sex Transm Infect. 2011;87(6):458-63. https://doi.org/10.1136/sextrans-2011-050073

  20. Tan LS, Chio MT, Sen P, Lim YK, Ng J, Ilancheran A, et al. Assessment of psychosocial impact of genital warts among patients in Singapore. Sex Health. 2014;11(4):313-8. https://doi.org/10.1071/SH13189

  21. Östensson E, Fröberg M, Leval A, Hellström AC, Bäcklund M, Zethraeus N, et al. Cost of preventing, managing, and treating Human Papillomavirus (HPV)-related diseases in Sweden before the introduction of quadrivalent HPV vaccination. PLoS One. 2015;10(9):e0139062. https:// doi.org/10.1371/journal.pone.0139062

  22. Strand A, Brinkeborn R, Siboulet A. Topical treatment of genital warts in men, an open study of podophyllotoxin cream compared with solution. Genitourinary medicine. 1995;71:387-90.

  23. Lacey CJ, Woodhall SC, Wikstrom A, Ross J. 2012 European guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol. 2013;27(3):e263-70. https://doi.org/10.1111/j.1468-3083.2012.04493.x

  24. Pichon-Riviere A, Alcaraz A, Caporale J, Bardach A, Rey-Ares L, Klein K, et al. Cost-effectiveness of quadrivalent vaccine against human papilloma virus in Argentina based on a dynamic transmission model. Salud Publica Mex. 2015;57(6):504-13. https://doi.org/10.21149/spm.v57i6.7639

  25. Lazcano-Ponce E, Pérez G, Cruz-Valdez A, Zamilpa L, Aranda-Flores C, Hernández-Nevarez P, et al. Impact of a quadrivalent HPV6/11/16/18 vaccine in Mexican women: public health implications for the region. Arch Med Res. 2009;40(6):514-24. https://doi.org/10.1016/j.arcmed.2009.07.008

  26. Donne AJ, Hampson L, Homer JJ, Hampson IN. The role of HPV type in Recurrent Respiratory Papillomatosis. Int J Pediatr Otorhinolaryngol. 2010;74(1):7-14. https://doi.org/10.1016/j.ijporl.2009.09.004

  27. Granados-García M. Oropharyngeal cancer: an emergent disease? Salud Publica Mex. 2016;58:285-90. https://doi.org/10.21149/spm.v58i2.7798

  28. Coles VA, Chapman R, Lanitis T, Carroll SM. The costs of managing genital warts in the UK by devolved nation: England, Scotland, Wales and Northern Ireland. Int J STD AIDS. 2016;27(1):51-7. https://doi. org/10.1177/0956462415573121

  29. King EM, Gilson R, Beddows S, Soldan K, Panwar K, Young C, et al. Human papillomavirus DNA in men who have sex with men: type-specific prevalence, risk factors and implications for vaccination strategies. Br J Cancer. 2015;112(9):1585-93. https://doi.org/10.1038/bjc.2015.90

  30. Jiménez-Vieyra CR. Prevalence of condyloma acuminata in women who went to opportune detection of cervicouterine cancer. Ginecol Obstet Mex. 2010;78(2):99-102.

  31. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105:175-201. https://doi.org/10.1093/jnci/djs491

  32. Chatuvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294-301. https://doi.org/10.1200/ JCO.2011.36.4596

  33. Frenk J, Gómez-Dantés O. Healthcare or sickcare: reestablishing the balance. Salud Publica Mex. 2016;58:84-8. https://doi.org/10.21149/spm. v58i1.7671

  34. Salmerón J, Torres-Ibarra L, Bosch FX, Cuzick J, Lörincz A, Wheeler CM, et al. HPV vaccination impact on a cervical cancer screening program: methods of the FASTER-Tlalpan Study in Mexico. Salud Publica Mex. 2016;58:211-9. https://doi.org/10.21149/spm.v58i2.7790

  35. Schmeler KM, Sturgis EM. Expanding the benefits of HPV vaccination to boys and men. Lancet. 2016;387(10030):1798-9. https://doi.org/10.1016/ S0140-6736(16)30314-2

  36. Winer RL, Hughes JP, Feng Q, Stern JE, Xi LF, Koutsky LA. Incident detection of high-risk Human Papillomavirus infections in a cohort of highrisk women aged 25-65 years. J Infect Dis. 2016;214(5):665-75. https://doi. org/10.1093/infdis/jiw074

  37. Nyitray AG, Carvalho da Silva RJ, Chang M, Baggio ML, Ingles DJ, Abrahamsen M, et al. Incidence, duration, persistence, and factors associated with high-risk anal HPV persistence among HIV-negative men having sex with men: A multi-national study. Clin Infect Dis. 2016;62(11):1367-74. https://doi.org/10.1093/cid/ciw140

  38. Garland SM, Subasinghe AK, Jayasinghe YL, Wark JD, Moscicki AB, Singer A, et al. HPV vaccination for victims of childhood sexual abuse. Lancet. 2015;386(10007):1919-20. https://doi.org/10.1016/S0140-6736(15)00757-6

  39. Stratton KL, Culkin DJ. A Contemporary Review of HPV and Penile Cancer. Oncology (Williston Park). 2016;30(3):245-9.




2020     |     www.medigraphic.com